What FDA’s record states
| Field | What FDA’s record states | Source |
|---|---|---|
| Recipient | AnuMed International, LLC | FDA letter ↗ |
| Location | Phoenix, AZ | FDA letter ↗ |
| Letter date | Aug 20, 2024 | FDA letter ↗ |
| Posted by FDA | Aug 27, 2024 | FDA index ↗ |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA letter ↗ |
| Subject | Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded | FDA letter ↗ |
| MARCS-CMS number | 674310 | FDA letter ↗ |
| GLP-1 drugs named | Semaglutide | FDA letter ↗ |
| Response letter | Not published by FDA | FDA letter ↗ |
| Closeout letter | Not published by FDA | FDA letter ↗ |
“Examples of claims from your product labeling and website https://www.anumed-intl.com/ that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following: Semaglutide Homeopathic Formula On the product label: • “CRAVINGS APPETITE WEIGHT LOSS” • “INDICATIONS: It may help to temporarily reduce minor hunger pangs and control appetite to support weight loss efforts.” • “DIRECTIONS: . . .”FDA warning letter to AnuMed International, LLC, Aug 20, 2024 · read the full letter on fda.gov ↗
What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.
Source
Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters